Grifols said the layoffs sparked by its restructuring represent just 8% of its workforce. But the cuts will happen mainly in the Barcelona-based company’s U.S. plasma operations, source of most of the plasma that is the basis for its biologic medicines.
Grifols's acquisition of GigaGen comes as the startup's Covid-19 antibody drug is set to start Phase 1 testing. Barcelona-based Grifols says GigaGen’s technology could also help it expand to engineered antibody therapies.
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
A review of life science current events reported by MedCity News this week: Grifols and Talecris get FTC approval to merge. The FTC had been concerned that a merger of two of the top companies in the specialized blood therapeutics space would hurt competition and lead to higher drug costs for patients. Cleveland Clinic CEO: […]
Grifols‘ (MCE:GRF) $4 billion acquisition of Talecris Biotherapeutics (NASDAQ:TLCR) now has the regulatory clearance to close. Barcelona, Spain-based Grifols said Wednesday that the U.S. Federal Trade Commission has accepted a consent agreement that outlines the conditions for merger of the blood therapeutics companies. Last month, the FTC and the companies reached a preliminary agreement that […]
Talecris Biotherapeutics’ (NASDAQ:TLCR) $4 billion acquisition by Spanish company Grifols (MCE:GRF) looks like it will finally win regulatory approval. Barcelona-based Grifols said Monday that it has reached a preliminary agreement with the U.S. Federal Trade Commission that grants approval of the deal, but also calls for both blood therapeutics companies to sell certain assets. The […]
The Talecris Biotherapeutics acquisition by Spanish company Grifols (MCE:GRF) looks like it’s moving closer to receiving regulatory approval, at least that’s how stock traders view the deal. Bloomberg Businessweek reports that investors have grown more bullish on Talecris (NASDAQ:TLCR), particularly since the Research Triangle Park, North Carolina company extended the deadline to close the $3.4 […]
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Talecris Biotherapeutics and Grifols are extending the closing date for their proposed $3.4 billion merger while Grifols continues to work with the U.S. Federal Trade Commission on clearing the deal.
Talecris Biotherapeutics released fourth-quarter financial results that saw net income shoot up to $17.1 million due in part to stronger revenue for its blood therapeutics drugs.
Among the life science current events from last week: GSK layoffs, the impact of the Talecris-Grifols merger; Ohio State University's $100 million donation; Steris' FDA warning letter; and RedBrick Health's foray into healthcare social media.